Form 4: KalVista Pharmaceuticals CFO Brian Piekos Reports Acquisition of 80,000 Restricted Stock Units
SEC Form 4 Filing
Brian Piekos, CFO of KalVista Pharmaceuticals, reports the acquisition of 80,000 restricted stock units (RSUs) on February 21, 2025, according to a Form 4 filing with the SEC.
Summary
- On February 21, 2025, Brian Piekos, the Chief Financial Officer of KalVista Pharmaceuticals, Inc., acquired 80,000 Restricted Stock Units (RSUs).
- Each RSU represents a contingent right to receive one share of KalVista's common stock upon settlement at no cost.
- The RSUs vest in installments, with 3/16 vesting on November 21, 2024, and 1/16 vesting quarterly thereafter, contingent upon continued service.
Sentiment
Score: 5
Explanation: This is a routine filing; sentiment is neutral as it reflects standard compensation practices.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- Shareholders may view this as part of the executive compensation package.
- Employees may see this as a standard practice for executive compensation.
Key Dates
| Date | Description |
|---|---|
| November 21, 2024 | Vesting Commencement Date: 3/16 of the RSUs vest. |
| February 21, 2025 | Transaction Date: CFO acquired 80,000 Restricted Stock Units. |
| February 25, 2025 | Date of Form 4 Filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.